Furthermore, we analyzed the levels of CAMKK2 expression in seven human glioblastoma patient-derived cell lines, maintained in neural stem cell medium under serum-free conditions [41] and found that all tumors showed 20–60% lower level of expression of CAMKK2 protein compared to normal frontal cortex (Fig 4E). This evidence concerns the gene CAMKK2 and glioblastoma.